Skip to main content
. 2020 Oct 29;38(1):52–75. doi: 10.1007/s12325-020-01524-6

Fig. 2.

Fig. 2

Actions of erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). IV intravenous